You are here

Article Text

Article menu

This article has a correction. Please see:

Download PDFPDF
Letter
HPV in cervix and vagina
  1. M Baay1,
  2. F Lardon1,
  3. J B Vermorken1,
  4. V Verhoeven2,
  5. D Avonts2,
  6. P Van Royen2,
  7. K Wouters3,
  8. P Van Damme4,
  9. E Van Marck5
  1. 1Department of Medical Oncology, University of Antwerp, Belgium
  2. 2Centre for General Practice, University of Antwerp, Belgium
  3. 3Health House for Prostitutes in Antwerp, University of Antwerp, Belgium
  4. 4Department of Epidemiology and Social Medicine, University of Antwerp, Belgium
  5. 5Department of Pathology, University of Antwerp, Belgium
  1. Correspondence to:
 Dr Marc F D Baay
 Department of Medical Oncology, University of Antwerp (CDE, T3), Universiteitsplein 1, 2610 Wilrijk, Belgium; Marc.Baayua.ac.be

https://doi.org/10.1136/sti.2003.008383

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Cervical cancer screening by Papanicolaou (Pap) smear has shown its use in reducing both incidence and mortality. Nowadays, cervical tumours are mostly diagnosed in women who were not, or not properly, screened. The invasive sampling method of screening is one of the reasons why women do not participate. The efficiency of cervical cancer screening could be increased if a less invasive test were available. Today, there is extensive scientific evidence that infection with high risk human papillomavirus (HPV) is associated with the development of cervical cancer. An international survey of more than 1000 cervical cancers showed that HPV DNA was present in 93% of all tumours. …

    View Full Text

    Footnotes

    • This study was financed in part by a research grant of the Fund for Scientific Research—Flanders (Belgium) to JBV.